Protagonist Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered board introductions, four key proposals, and voting procedures. All proposals—including director elections, executive compensation, auditor ratification, and the equity incentive plan—were approved. Voting results will be filed with the SEC.
-
The company is advancing as a commercial-stage biotech with strong financials, highlighted by Icotyde's successful launch and anticipated Rusfertide approval. Its robust, de-risked pipeline includes innovative oral peptides for I&I and obesity, with strategic partnerships and shareholder rewards planned.
-
Strong royalty streams from major partnerships and a robust, de-risked pipeline support self-funded R&D and potential share buybacks. ICOTYDE is positioned for major growth, while rusfertide's opt-out deal secures significant payments and high royalties. Multiple innovative programs advance toward key milestones.
-
ICOTYDE, the first oral IL-23 receptor blocker, received FDA approval for moderate-to-severe plaque psoriasis, supported by robust phase III data and a clean safety profile. The approval triggers significant milestone payments and positions the product as a needle-free alternative to injectables, with ongoing studies in additional indications and a strong financial outlook.
-
The discussion highlighted a robust pipeline of novel oral and injectable peptide therapeutics, with two lead assets nearing potential approval and a diversified R&D focus in immunology, hematology, and obesity. Strategic partnerships and financial strength support continued innovation and market expansion.
-
The company leverages deep expertise in peptide therapeutics, with two late-stage partnered assets expected to receive regulatory decisions in Q3. Strong partnerships, a robust pipeline in I&I and obesity, and a solid financial position enable continued innovation and multiple value inflection points in 2026.
-
Two partnered products are expected to receive FDA approval in 2026, with significant milestone payments and surplus cash anticipated. The pipeline features first-in-class oral IL-23 and IL-17 assets, innovative obesity candidates, and a robust peptide platform, positioning for market disruption and shareholder value creation.
-
The session highlighted a robust pipeline with two near-term launches, strong clinical data for oral IL-23 in psoriasis and IBD, and significant market opportunities. Strategic partnerships, financial independence, and a focus on innovation and differentiation underpin future growth.
-
Significant growth is expected over the next two years with two near-term product launches, a robust pipeline of fully owned and partnered assets, and strong financials supporting both R&D and shareholder returns. Strategic focus includes expanding discovery, pharma partnerships for large markets, and operational scaling.
Fiscal Year 2025
-
Breakthrough designation was regained for rusfertide after strong phase 3 results in polycythemia vera, with NDA filing planned by year-end and a $1–2 billion market opportunity. Strategic opt-in/opt-out decisions could fund R&D and share buybacks. Pipeline assets show strong differentiation and clinical progress.
-
The summit highlighted advances in peptide therapeutics, with rusfertide progressing toward NDA filing and a strategic partnership with Takeda. Icotrokinra's strong clinical profile and J&J partnership position it for significant market impact, while new obesity and IL-17 programs expand the pipeline.
-
PN-477, a novel oral and injectable triple agonist for obesity, was nominated as a development candidate, showing strong preclinical efficacy, favorable pharmacokinetics, and potential for best-in-class status. Both formulations will advance in parallel, supported by a robust cash position and strategic flexibility.
-
ASCO plenary data showed a new PV drug with strong efficacy, symptom improvement, and safety, earning "practice-changing" recognition and support for standard of care adoption. Strategic partnerships with Takeda and J&J drive late-stage and early pipeline progress, while robust financial prospects prompt a focus on capital allocation.
-
VERIFY phase III results show rusfertide significantly improves hematocrit control, reduces phlebotomy needs, and enhances quality of life in PV patients, with a favorable safety profile. Regulatory filing is planned for Q4 2025, and commercial prospects are strong.
-
Rusfertide achieved robust efficacy and safety in the phase III VERIFY study for polycythemia vera, meeting all primary and secondary endpoints and showing significant improvements in clinical response and patient-reported outcomes. Regulatory filings are planned with strong commercial potential and continued collaboration with Takeda.
-
Rusfertide demonstrated rapid and sustained hematocrit control, reduced phlebotomy need, and improved symptoms in phase II PV studies, with a favorable safety profile. The ongoing phase III VERIFY trial is expected to confirm these benefits and support broad adoption, targeting a significant unmet need in PV.
-
The session highlighted robust progress in peptide therapeutics, with late-stage assets rusfertide and icotrokinra targeting NDA filings by year-end and significant market potential. Discovery programs in IL-17, obesity, and oral hepcidin are advancing, supported by strong partnerships and a cash runway through 2028.
Fiscal Year 2024
-
Icotrokinra, an oral IL-23 blocker, achieved strong phase III results and is set to launch as the leading oral psoriasis therapy, with a robust royalty structure and high patient satisfaction. The pipeline includes a potent oral IL-17 candidate and an obesity program, both advancing toward clinical milestones.
-
PN-881, a fully owned oral IL-17 antagonist, was nominated as a development candidate, showing best-in-class potency and strong preclinical results. With a robust cash runway, the company plans to advance PN-881 into clinical trials and expand its pipeline, while maintaining strategic flexibility.
-
Multiple phase III studies for oral peptide therapeutics in psoriasis, ulcerative colitis, and polycythemia vera are progressing, with key data expected by year-end and early next year. Strategic partnerships with J&J and Takeda offer significant milestone and royalty opportunities, while the pipeline expands into IL-17 and obesity indications.
-
Two late-stage assets, JNJ-2113 and rusfertide, are advancing rapidly, with key data readouts expected by year-end and early next year. Strong partnerships, a robust cash position, and a growing early pipeline support ongoing innovation and potential commercialization.